These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 35703179

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
    Alessi Wolken DM, Idone V, Hatsell SJ, Yu PB, Economides AN.
    Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
    [Abstract] [Full Text] [Related]

  • 3. The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva.
    Ye Z, Wang S, Shan C, Zhu Q, Xue Y, Zhang K.
    Orphanet J Rare Dis; 2023 May 10; 18(1):111. PubMed ID: 37165433
    [Abstract] [Full Text] [Related]

  • 4. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
    Towler OW, Shore EM.
    Dev Dyn; 2022 Jan 10; 251(1):164-177. PubMed ID: 34133058
    [Abstract] [Full Text] [Related]

  • 5. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
    Barruet E, Morales BM, Lwin W, White MP, Theodoris CV, Kim H, Urrutia A, Wong SA, Srivastava D, Hsiao EC.
    Stem Cell Res Ther; 2016 Aug 17; 7(1):115. PubMed ID: 27530160
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.
    Aykul S, Huang L, Wang L, Das NM, Reisman S, Ray Y, Zhang Q, Rothman N, Nannuru KC, Kamat V, Brydges S, Troncone L, Johnsen L, Yu PB, Fazio S, Lees-Shepard J, Schutz K, Murphy AJ, Economides AN, Idone V, Hatsell SJ.
    J Clin Invest; 2022 Jun 15; 132(12):. PubMed ID: 35511419
    [Abstract] [Full Text] [Related]

  • 8. An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.
    Lees-Shepard JB, Stoessel SJ, Chandler JT, Bouchard K, Bento P, Apuzzo LN, Devarakonda PM, Hunter JW, Goldhamer DJ.
    J Clin Invest; 2022 Jun 15; 132(12):. PubMed ID: 35503416
    [Abstract] [Full Text] [Related]

  • 9. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva.
    Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, Kaplan FS, Shore EM.
    J Bone Miner Res; 2018 Feb 15; 33(2):269-282. PubMed ID: 28986986
    [Abstract] [Full Text] [Related]

  • 10. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1R206H -Specific Human Cellular and Zebrafish Models.
    Wentworth KL, Lalonde RL, Groppe JC, Brewer N, Moody T, Hansberry S, Taylor KE, Shore EM, Kaplan FS, Pignolo RJ, Yelick PC, Hsiao EC.
    J Bone Miner Res; 2022 Nov 15; 37(11):2058-2076. PubMed ID: 36153796
    [Abstract] [Full Text] [Related]

  • 11. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).
    Wang H, Shore EM, Pignolo RJ, Kaplan FS.
    Bone; 2018 Apr 15; 109():218-224. PubMed ID: 29170109
    [Abstract] [Full Text] [Related]

  • 12. Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients.
    Wang H, De Cunto CL, Pignolo RJ, Kaplan FS.
    Bone; 2021 Aug 15; 149():115978. PubMed ID: 33915334
    [Abstract] [Full Text] [Related]

  • 13. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ, Idone V, Wolken DM, Huang L, Kim HJ, Wang L, Wen X, Nannuru KC, Jimenez J, Xie L, Das N, Makhoul G, Chernomorsky R, D'Ambrosio D, Corpina RA, Schoenherr CJ, Feeley K, Yu PB, Yancopoulos GD, Murphy AJ, Economides AN.
    Sci Transl Med; 2015 Sep 02; 7(303):303ra137. PubMed ID: 26333933
    [Abstract] [Full Text] [Related]

  • 14. iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
    Gao P, Inada Y, Hotta A, Sakurai H, Ikeya M.
    Stem Cell Res Ther; 2024 Mar 18; 15(1):83. PubMed ID: 38500216
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
    Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, Hoover-Fong J, Köster B, Pauli RM, Reardon W, Zaidi SA, Zasloff M, Morhart R, Mundlos S, Groppe J, Shore EM.
    Hum Mutat; 2009 Mar 18; 30(3):379-90. PubMed ID: 19085907
    [Abstract] [Full Text] [Related]

  • 17. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
    Chakkalakal SA, Uchibe K, Convente MR, Zhang D, Economides AN, Kaplan FS, Pacifici M, Iwamoto M, Shore EM.
    J Bone Miner Res; 2016 Sep 18; 31(9):1666-75. PubMed ID: 26896819
    [Abstract] [Full Text] [Related]

  • 18. Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.
    Kaplan FS, Al Mukaddam M, Stanley A, Towler OW, Shore EM.
    Bone; 2020 Nov 18; 140():115539. PubMed ID: 32730934
    [Abstract] [Full Text] [Related]

  • 19. Granting immunity to FOP and catching heterotopic ossification in the Act.
    Kaplan FS, Pignolo RJ, Shore EM.
    Semin Cell Dev Biol; 2016 Jan 18; 49():30-6. PubMed ID: 26706149
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.